From the floor in Nantong: 15 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Archive — April 2025
Page 5 of 5 of this archive, newest first.
Medutest result on a Tianjin semaglutide lot lands 2.4 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
What changed at JEEP in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why a result on one vial says less than the trade needs it to
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
SURMOUNT-OSA was built to answer the stopping question, and it did
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Five lines that would change what a certificate is worth
The Journal wrote to twenty companies asking five specific questions about sterility assurance. We report the response rate, the substance and the refusals.
The Netherlands pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
The Netherlands health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
Hangzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.